Plitidepsin

N/A

Report date: 2022/01/14 13:23:58
NMEFirst In Class

Base Information

Drug NamePlitidepsin
Drug Alias Name普利迪星Plitidepsine普利肽新Dehydrodidemnin BPlitidepsinum +[9] 
ClassificationSmall molecules > Synthetic peptideNatural product/Extract
Mechanisms of ActionVascular endothelial growth factor receptor 1 antagonists
TargetsVascular endothelial growth factor receptor 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursPost-Acute COVID-19 Syndrome +[10] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryAustralia
Original Approved Date2018/12/11
Country/TerritoryCzechiaBelgiumUnited States +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPharma Mar Sa
China Registration ClassN/A

Develop Information

Active CompaniesPharma Mar Sa
Inactive CompaniesInstitut Bergonié
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeMultiple Myeloma
Inactive IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaPrimary Myelofibrosis +[7] 

Other Information

ATC CodeL01XX57
Related LinksWikipediaDrugBankKEGG